Morgan Stanley’s ProShares Ultra CRCL CRCA Stock Holding History

Morgan Stanley’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$537K	Buy	13,000 +11,760	+948%	+$488K	﹤0.01%	5452
2025 Q4	$50.1K	Buy	1,240 +540	+77%	+$46.3K	﹤0.01%	6440
2025 Q3	$102K	Buy	+700	New	+$113K	﹤0.01%	6140

Other funds holding CRCA

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley's CRCA Position: Q1 2026 in Review

Morgan Stanley increased its ProShares Ultra CRCL (CRCA) stake by 948% in Q1 2026, buying an estimated $488K and bringing the position to 13,000 shares worth $537K. The position accounts for ﹤0.01% of the portfolio, ranked #5452.

Morgan Stanley first reported a position in CRCA in Q3 2025 and has held it in 3 quarters since. 7 funds tracked by Wall St. Rank hold CRCA as of Q1 2026.

Morgan Stanley held 13,000 shares of ProShares Ultra CRCL worth $537K as of Q1 2026.
Morgan Stanley bought 11,760 ProShares Ultra CRCL shares in Q1 2026, an estimated $488K.
ProShares Ultra CRCL made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5452 holding.
Morgan Stanley first reported a position in ProShares Ultra CRCL in Q3 2025 and has held it in 3 quarters since.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.